Details of the Drug-Related molecule(s) Interaction Atlas

R-568 Drug Info

Tecalcet; Tecalcet [INN]; NPS-R-568; UNII-8I16YLE4US; R 568; NPS R 568; NPS R-568; 148717-54-8; 8I16YLE4US; CHEMBL292376; (R)-2-Chloro-N-(1-(3-methoxyphenyl)ethyl)benzenepropanamine; Benzenepropanamine, 2-chloro-N-(1-(3-methoxyphenyl)ethyl)-, (R)-; 3-(2-chlorophenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]propan-1-amine; AC1L4KMU; GTPL718; SCHEMBL311950; NPS R568; DTXSID90164084; ZVQUCWXZCKWZBP-CQSZACIVSA-N; ZINC1538900; BDBM50432960; BDBM50299670; NCGC00344508-01; LS-31029; KB-80823

Cross-matching ID

PubChem CID

158796

CAS Number

CAS 177172-49-5

TTD Drug ID

DM5NWPD

General Information of Drug (ID: DM5NWPD)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Preclinical Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular calcium-sensing receptor (CASR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[2]
Etelcalcetide	DMHP9BL	Secondary hyperparathyroidism	5A51.1	Approved	[3]
Encaleret	DMQSPFS	Autosomal dominant hypocalcemia	5A50.0Y	Phase 3	[4]
ASP7991	DM3TN1A	Hyperparathyroidism	5A51	Phase 2	[5]
MK-5442	DMHTIGU	Osteoporosis	FB83.0	Phase 2	[6]
ATF-936	DMWGKHZ	Osteoporosis	FB83.0	Phase 1	[7]
AXT-914	DM7ZU3B	Osteoporosis	FB83.0	Phase 1	[8]
Ronacaleret	DM10ZJP	Osteoporosis	FB83.0	Discontinued in Phase 2	[9]
NPS-2143	DMQPXLF	Osteoporosis	FB83.0	Discontinued in Phase 2	[10]
NPS-2390	DMMRY0Z	Cerebrovascular ischaemia	8B1Z	Preclinical	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Extracellular calcium-sensing receptor (CASR)	TTBUYHA	CASR_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

References

1	Mixed-effects modeling of the pharmacodynamic response to the calcimimetic agent R-568. Clin Pharmacol Ther. 1999 Jan;65(1):40-9.
2	Clinical pipeline report, company report or official report of Amgen (2009).
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035616)
6	Antagonist for calcium-sensing receptor. JTT-305/MK-5442. Clin Calcium. 2011 Jan;21(1):89-93.
7	ATF936, a novel oral calcilytic, increases bone mineral density in rats and transiently releases parathyroid hormone in humans. Bone. 2011 Aug;49(2):233-41.
8	AXT914 a novel, orally-active parathyroid hormone-releasing drug in two early studies of healthy volunteers and postmenopausal women. Bone. 2014 Jul;64:204-10.
9	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10	Calcium-sensing receptor antagonist (calcilytic) NPS 2143 specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic relevance to Alzheimer's disease. Biochim Biophys Acta. 2013 Oct;1832(10):1634-52.
11	The Extracellular Calcium-Sensing Receptor (CASR) Regulates Gonadotropins-Induced Meiotic Maturation of Porcine Oocytes.Biol Reprod.2015 Dec;93(6):131.